연구
교육
솔루션
로그인
KR
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Türkçe
JA - 日本語
PL - Polski
RU - Русский
HE - עִברִית
AR - العربية
Translational Medicine,
R&D Oncology,
Translational Medicine, R&D Oncology
Melanie M. Frigault has not added Biography.
If you are Melanie M. Frigault and would like to personalize this page please email our Author Liaison for assistance.
Are companion diagnostics useful?
Clinical chemistry Jan, 2013 | Pubmed ID: 23193059
Is target validation all we need?
Current opinion in pharmacology Aug, 2014 | Pubmed ID: 25261632
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Clinical cancer research : an official journal of the American Association for Cancer Research Jun, 2015 | Pubmed ID: 25779944
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Sep, 2017 | Pubmed ID: 28644771
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 08, 2019 | Pubmed ID: 30952639
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Blood advances 05, 2019 | Pubmed ID: 31088809
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Blood 04, 2020 | Pubmed ID: 31876911
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Cancer discovery 03, 2020 | Pubmed ID: 31915195
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
JAMA oncology 08, 2020 | Pubmed ID: 32469384
A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.
Cell reports 07, 2020 | Pubmed ID: 32668248
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in -Amplified Gastric Cancer.
JCO precision oncology , 2020 | Pubmed ID: 32923890
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Investigational new drugs Apr, 2021 | Pubmed ID: 33052556
AstraZeneca
Paola Marco-Casanova1,
Natalia Lukashchuk1,
Benedetta Lombardi1,
Veerendra Munugalavadla2,
Melanie M. Frigault3,
Elizabeth A. Harrington1,
J. Carl Barrett3,
Andrew J. Pierce1
1Translational Medicine, R&D Oncology, AstraZeneca,
2, Acerta Pharma, AstraZeneca Group,
3Translational Medicine, R&D Oncology, AstraZeneca
개인 정보 보호
이용 약관
정책
연락처
사서에게 추천하기
JoVE 뉴스레터
JoVE Journal
연구 방법 컬렉션
JoVE Encyclopedia of Experiments
아카이브
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
교수 리소스 센터
저자
사서
액세스
JoVE 소개
Copyright © 2025 MyJoVE Corporation. 판권 소유
당사 웹 사이트에서는 사용자의 경험을 향상시키기 위해 쿠키를 사용합니다.
당사 웹 사이트를 계속 사용하거나 '계속'을 클릭하는 것은 당사 쿠키 수락에 동의하는 것을 의미합니다.
더 알아보기